{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NYSE/CPHI",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# CHINA PHARMA HOLDINGS, INC. (NYSE: CPHI) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nCHINA PHARMA HOLDINGS, INC. is listed on the NYSE under ticker CPHI, ISIN US16941T4013, LEI 529900B3Q0CRC8OASE20. Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States — Delaware. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 14 filings in the twelve months to 2026-11-08, on 13 filing days. The filings comprise 3 AGM/EGM, 5 corporate news, 1 prospectus, 1 regulatory filing and 4 results. The median gap between filing days is 24.0 days, against 6.0 days for the NYSE and 6.0 days for sector 2834 Pharmaceutical Preparations. The latest filing is dated 2026-10-30 and is of type AGM/EGM. It was 9 days before the record date, against a latency median of 4.0 days for the NYSE and 4.0 days for the sector, and the issuer's median filing count is 14, against 64.0 for the NYSE and 63.0 for the sector.\n\n## Auditor\n\nThe auditor of record is Enrome LLP, located in Singapore. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change events. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag is listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable for the US rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, chapter as of 2026-11-04, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category.\n\n## Coverage\n\nNo research houses were found on the investor-relations pages read, and the count is 0.\n\n## Open research\n\nNo openly published research notes were found, and the count is 0.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe issuer is sealed for the years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.\n\n## Sources\n\n9 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest (identity.isin)\n- https://data.sec.gov/submissions/CIK0001106644.json (identity.jurisdiction)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.us-cm-kg.ai/events/NYSE/CPHI (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.us-cm-kg.ai/record/NYSE/CPHI (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm",
    "state": "sourced",
    "value": "Enrome LLP"
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm",
    "state": "sourced",
    "value": "6907"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm",
    "state": "sourced",
    "value": "Singapore"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NYSE/CPHI",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 3256,
     "median_cadence_gap_days": 6,
     "median_filings": 64,
     "median_latency_days": 4,
     "name": "NYSE"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 3,
    "corporate_news": 5,
    "prospectus": 1,
    "regulatory_filing": 1,
    "results": 4
   },
   "cadence_median_gap_days": 24,
   "filing_days": 13,
   "filings": 14,
   "latency_days": 9,
   "latest": [
    {
     "category": "PRE 14A",
     "date": "2026-10-30",
     "source": "https://www.sec.gov/Archives/edgar/data/1106644/000121390026114445/ea0310270-pre14a_chinapharma.htm",
     "title": "PRE 14A — PRELIMINARY PROXY STATEMENT",
     "type": "agm_egm"
    },
    {
     "category": "10-Q",
     "date": "2026-08-14",
     "source": "https://www.sec.gov/Archives/edgar/data/1106644/000121390026090173/ea0301830-10q_china.htm",
     "title": "10-Q — QUARTERLY REPORT",
     "type": "results"
    },
    {
     "category": "424B5",
     "date": "2026-07-23",
     "source": "https://www.sec.gov/Archives/edgar/data/1106644/000121390026080581/ea0298951-424b5_china.htm",
     "title": "424B5 — PROSPECTUS SUPPLEMENT",
     "type": "prospectus"
    },
    {
     "category": "8-K",
     "date": "2026-07-22",
     "source": "https://www.sec.gov/Archives/edgar/data/1106644/000121390026080475/ea0298921-8k_china.htm",
     "title": "8-K — CURRENT REPORT (items 1.01,8.01,9.01)",
     "type": "corporate_news"
    },
    {
     "category": "10-Q",
     "date": "2026-05-15",
     "source": "https://www.sec.gov/Archives/edgar/data/1106644/000121390026057705/ea0290433-10q_china.htm",
     "title": "10-Q — QUARTERLY REPORT",
     "type": "results"
    }
   ],
   "latest_filing_date": "2026-10-30",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/CPHI",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NYSE"
   },
   "isin": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (ISINs mapped to the LEI)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest",
    "state": "sourced",
    "value": "US16941T4013"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001106644.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-08",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN US16941T4013)",
    "state": "sourced",
    "value": "529900B3Q0CRC8OASE20"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001106644.json",
    "state": "sourced",
    "value": "CHINA PHARMA HOLDINGS, INC."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001106644.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001106644.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "CPHI"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:81d753ba55071f9b8ac0b8d3c48b127292e16e65855a736c9dbcec58b1b38c91",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NYSE/CPHI",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:81d753ba55071f9b8ac0b8d3c48b127292e16e65855a736c9dbcec58b1b38c91",
 "path": "/us/NYSE/CPHI",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "CHINA PHARMA HOLDINGS, INC. is listed on the NYSE under ticker CPHI, ISIN US16941T4013, LEI 529900B3Q0CRC8OASE20. Its security type is Corporate, its segment is not on the record, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States — Delaware. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 14 filings in the twelve months to 2026-11-08, on 13 filing days. The filings comprise 3 AGM/EGM, 5 corporate news, 1 prospectus, 1 regulatory filing and 4 results. The median gap between filing days is 24.0 days, against 6.0 days for the NYSE and 6.0 days for sector 2834 Pharmaceutical Preparations. The latest filing is dated 2026-10-30 and is of type AGM/EGM. It was 9 days before the record date, against a latency median of 4.0 days for the NYSE and 4.0 days for the sector, and the issuer's median filing count is 14, against 64.0 for the NYSE and 63.0 for the sector.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is Enrome LLP, located in Singapore. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change events. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable for the US rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, chapter as of 2026-11-04, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "No research houses were found on the investor-relations pages read, and the count is 0.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found, and the count is 0.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The issuer is sealed for the years 2021, 2022, 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "9 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001106644.json"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/CPHI"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1106644/000121390026038521/ea0283939-10k_china.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NYSE/CPHI"
  }
 ],
 "title": "CHINA PHARMA HOLDINGS, INC. (CPHI) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}